The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.
For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.
For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at http://www.nccn.org/ clinical_trials/clinicians.asp.
Highlights of the NCCN Oncology Research Program
The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. This is an open-label, phase I, dose-escalation safety study of bortezomib in combination with pralatrexate in patients with previously treated multiple myeloma. In a standard 3 + 3 dose escalation trial design, escalating doses of pralatrexate in combination with bortezomib will be studied until the maximum tolerated dose (MTD) is determined. Primary Objectives:
• Determine the MTD for combination pralatrexate and VELCADE in previously treated adult patients with multiple myeloma Secondary Objectives:
• Clinical evidence of antitumor activity based on response rates • Time to progression (TTP) assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3 to 5, then annually thereafter • Duration of response outcome assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3 to 5, then annually thereafter • Progression-free survival assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3 to 5, then annually thereafter • Overall survival assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3 to 5, then annually thereafter 
